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Abstract
Objective: Growth hormone (GH) was shown to stimulate proliferation, migration and 
survival of neural cells in animal models. GH deficiency (GHD) was reported following 
traumatic brain lesions; however, there are not available data in spinal cord injury (SCI) 
patients. The aim of the study was to evaluate (1) the frequency of GHD in chronic 
SCI population; (2) the efficacy/safety of GH replacement in patients with SCI and 
suboptimal GH secretion.
Design and methods: Nineteen consecutive patients with chronic thoracic complete SCI 
(AIS-A) were studied. Patients with low GH secretion were randomized in a double-
blind, placebo-controlled study to receive either subcutaneous placebo injections or 
GH combined with physical therapy, for 6 months. Baseline cranial MRI, AIS motor and 
sensory scale, quality of life (spinal cord impact measurement) and modified Ashworth 
spasticity scale, quantitative sensory testing and neurophysiological exploration were 
assessed at baseline, 1, 3 and 6 months following treatment.
Results: Thirteen had GH deficiency. Seven received GH, five placebo and one dropped 
out. Both groups were similar according to clinical and demographical data at baseline, 
except for greater GH deficiency in the GH treatment group. At 6th month, patients 
treated with GH showed a significant improvement in SCIM-III score and in electrical 
perception threshold up to the 5th level below SCI, on both sides compared to baseline.
Conclusions: GHD seems to be frequent in traumatic SCI and GH replacement is safe 
without side effects. GH combined with physical therapy can improve quality of life of 
SCI patients and, strikingly, the sensory perception below lesion level.
Introduction
Growth hormone deficiency (GHD) has been studied in 
neurological disorders affecting central nervous systems, 
such as multiple sclerosis to amyotrophic lateral sclerosis 
(1, 2). Because of the direct impact to the pituitary area, 
transient GHD was reported following traumatic brain 
injury and subarachnoid hemorrhage. Around 25% 
of traumatic brain injury (TBI) patients remain with 
persistent GHD after 1  year, and this accounts for their 
cognitive and rehabilitation outcomes (3). Some case 
report was published (7) and the work done in transitional 
rodent models (8, 9, 10) focused our attention on the 
potential of GH for neurologic improvement in SCI. 
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However, in humans, very little is known about GH 
deficiency in spinal cord injury (SCI) (4, 5) despite having a 
high social impact since they mostly involve young people 
(61.4% between 14 and 44 years of age). Their incidence 
in Spain is considered around 2.5/100,000 persons/year, 
road accidents being the main cause (43.7%). Male/female 
ratio stands at 3.9/1, tetraplegia (cervical lesions) accounts 
for 38.5% of the cases and complete injuries affect 56.7% 
of the patients (6).
As known, GH mediates its action mainly on 
the liver acting through IGF1 synthesis and partially 
through IGF2 (bone) or MGF (muscle), on an endocrine 
pathway. Nevertheless an important paracrine effect 
has also been described, particularly in the central 
nervous system (2), and this has been hypothesized 
to be a potential action for pain modulation in 
GH-deficient fibromyalgic patients (11). Endogenous 
GH secretion depends on peptides such as somatostatin 
or GHRH, acting as neurotransmitters, but closing a 
negative feedback loop, GH and IGF1 may also act 
as neurotransmitters in a paracrine manner. There is 
evidence of blood–brain barrier crossing and GH/IGF1 
receptors have been described in all neurologic cells 
(neurons, oligodendrocytes, astrocytes) and neuronal 
stem cells (both in hippocampal glial precursors and 
spinal ependymal precursors) (12). GH was shown to 
stimulate proliferation, differentiation, migration and 
survival of astrocytes and oligodendrocytes in animal 
models. This could be in part because of a GH-mediated 
neuronal anti-apoptotic effect (Akt signaling pathway) 
both in animals and humans, as seen in vitro (13).
In order to assess (1) frequency of GHD in chronic 
SCI patients and (2) the efficacy and safety of GH 
replacement therapy in SCI patients with GH deficiency, 
we designed a prospective, phase II, double-blind, 
placebo control study.
Subjects and methods
Fifty-one consecutive outwards patients from specialized 
Neurorehabilitation Hospital were screened. Nineteen 
patients were finally included in this study (Fig. 1) (14). 
They all had complete (AIS-A) spine cord injury (SCI) 
(15), exclusively affecting thoracic neurological level, 
and a time-lapse spent from the lesion between 1 until 
2 years (chronic SCI). The exclusion criteria were acute or 
subacute SCI; lumbar lesion, incomplete SCI (AIS-B or C 
or D), concomitant TBI, pressure sores, articular limitation 
or unstable medical condition.
Protocol of GHD analytical assessment
All MRI done at the onset of SCI were reviewed to 
confirm pituitary integrity. GH secretion was performed 
with intramuscular glucagon test for under standardized 
procedure during 180 min. Peak GH at any point more 
than 10 ng/mL was considered as a normal response, 
and less than 3 ng/mL as the cut-off for severe deficiency, 
following current guidelines (16, 17).
GH was measured in a central laboratory using an 
automated chemiluminescent immunoassay from a 
commercial source (IMMULITE 2000; Diagnostic Products 
Corp., Los Angeles, CA, USA). The inter-assay coefficient 
of variation of the GH assays was 4.52%. The functional 
sensitivity of GH assays was 0.05 ng/mL. Baseline cortisol 
and TSH as well as basic blood analysis including glucose, 
total cholesterol, HDL cholesterol, LDL cholesterol, 
triglycerides, liver, renal parameters and blood count, 
were performed at baseline (T0) and at 3  months of 
treatment (T3).
Clinical assessment
BMI, waist circumference, lower and upper limbs 
diameter were registered at T0, T3 and T6 time point. 
For SCI assessment, we used ASIA (American Spine 
Injury Association) Scale (AIS) (international standards 
for neurological classification of spinal cord injury) for 
sensory perception and motor score (18), SCIM-III (Spinal 
Cord Impact measurement) to evaluate the quality of 
live and functional recovery (19), modified Ashworth 
scales for spasticity (20) and neurophysiological tests 
(Motor (MEPs) and somatosensory evoked potentials 
(SEPs) to evaluate motor and somatosensory conduction 
and electrical perception (EPT) and electrical pain 
perception threshold (EPPT) to evaluate small changes 
in sensory and pain perception) were assessed (21, 22, 
23). For the assessment of MEPs of tibialis anterior, 
and abductor hallucis (AH) muscles bilaterally, single 
magnetic stimuli were generated by a magnetic 
stimulator (Magstimsuper-rapid, Magstim Company, 
Spring Gardens, Whitland, UK) and delivered through 
a double cone coil centered over the vertex at rest or 
performing or imagining bilateral foot dorsiflexion 
during stimulus delivery with maximum stimulator 
output. We realized 4 single recordings, filtered between 
10 Hz and 10 kHz and amplified with a gain of 0.1 mV/div. 
SEPs (Cz–Fz) were obtained following retro-maleolar 
tibial nerve electrical stimulation of 1 ms duration 
delivered at a 3 Hz rate with a maximal intensity of 
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30 mA. Two sets of 300 responses were averaged with 
100 ms of sweeps, at 3 Hz and 3000 Hz of filters, and at a 
gain of 1 μv/div.
Electrical perception and electrical pain 
perception threshold
To investigate subclinical differences, we performed a 
sensory responsiveness quantification using electrical 
perception threshold (EPT) and EPPT at baseline (T0), 
T1, T3 and T6 (1, 3, 6 months). They were done in seven 
dermatomes bilaterally: at the neurological level (0) and 
at the first, second and fifth dermatomes rostral (1+, 2+, 
5+) and caudal (1−, 2−, 5−) to the neurological level. The 
participants were in a supine position on a bed in a quiet 
room throughout the test.
Pediatric ECG electrodes (cathode) with a diameter of 
18 mm (3M Red DotTM, type 2248) were attached over 
the AIS sensory key points. A ground inactive electrode 
attached to the ankle joint. The fifth dermatome rostral 
to the lesion was tested first, so that the patient was 
able to experience the stimulation in a dermatome with 
intact sensation. Then, each of the subsequent lower 
dermatomes was tested.
For every dermatome tested, the stimulus intensity 
was manually increased (increased the current in 
steps of 0.1 mA for EPT and 0.3 mA for EPPT) until the 
participant first reported the sensation (ascending) 
under the cathode. A stimulus of 0.5 ms duration 
delivered at 3 Hz (maximum stimulation applied: 
40 mA) (21).
Experimental procedure
Those with abnormal GH secretion (n = 13, 12 males 1 
female) were randomized (computer-based) in a double-
blind, placebo-controlled study. They received identical 
subcutaneous injections of either placebo (n = 5) or GH 
(Nutropin Aq) (0.0125 mg/kg/day) (n = 7) 6  days a week 
together with rehabilitation, for 6 months.
Figure 1
Consort 2010 flow diagram of the study.
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GH dosage was titrated according to physiological 
IGF1 levels measured at T1 and T3 (un-blind investigator). 
A paired up or down-titration was also done in the 
placebo group. IGF1 was measured at T1 and T3, using the 
same chemiluminescent assay. The inter-assay coefficient 
of variation of IGF-1 was 3.04% and the sensitivity of 
IGF-1 assay was <25 ng/mL (IMMULITE 2000; Diagnostic 
Products Corp.).
Physical therapy consisted of 2 h a day for 5 days a 
week for 6 months in a specialized program, done both in 
the GH and placebo groups.
Statistical analysis
SAS version 9.4 was used for statistical analysis. Because 
of the low number of patients included (n = 13) and 
non-normally distributed data, we used non-parametric 
analysis. Mann–Whitney U test was used to compare 
the data between the GH and placebo groups and 
Wilcoxon-t test to compare the changes in the same group 
in comparison to baseline. The comparison between 
groups of categorical variables (sex, BMI categories, SCI 
etiology groups, presence of previous spasticity, presence 
of previous rehabilitation) was performed using Fisher’s 
exact or chi-square tests, values expressed as mean ± s.d. 
The mean and standard deviation (s.d.) of EPT and EPPT 
value for each dermatome were calculated from three 
values at different time point evaluation (at baseline, 
T0, T1, T3 and T6). Changes in EPT and EPPT values 
at T1, T3 and T6 were tested using the Wilcoxon-t and 
Friedman tests in comparison to T0 (22, 23). EPT and 
EPPT comparisons between groups were analyzed, in each 
side, using a mixed linear model.
The study was approved by the ‘Hospital Quiron-
Teknon’ independent Ethical Committee. The trial 
has been registered (EudraCT 2011-005377-23) and 
approved by the Spanish Drug Agency. It was conducted 
in accordance with the Declaration of Helsinki and all 
patients gave written informed consent before their 
inclusion in the study.
Results
13/19 patients showed a suboptimal GH secretion and 
were randomized (7 received GH + physical therapy and 
6 placebo + physical therapy). One patient dropped out 
from the study (prisoned). Results are then expressed 
Table 1 Individual clinical data.
Age Sex










37 F 17 A Th 11 Bicycle accident 16 No No
24 M 13 A Th 11 Traffic accident 4.3 Yes GH
43 F 12 A Th 4 Work accident 6.8 Yes Placebo
39 M 18 A Th 4 Traffic accident 1.9 Yes GH
27 M 24 A Th 4 Traffic accident 7.4 Yes Placebo
24 M 16 A Th 5 Falling from three 2.6 Yes GH
63 F 13 A Th1 Traffic accident 14 No No
41 F 23 A Th 1 Traffic accident 24 No No
51 M 23 A Th 7 Bicycle accident 4.5 Yes Placebo
34 M 13 A Th 1 Gun shot 0.2 Yes GH
43 F 12 A Th 8 Falling from height 16 No no
24 M 20 A Th 6 Traffic accident 5.4 Yes Placebo
46 M 23 A Th 1 Falling from horse 0.3 Yes GH
25 M 18 A Th 11 Work accident 4.3 Yes Placebo
50 M 13 A Th 1 Falling from height 0.9 Yes GH
45 M 21 A Th 6 Traffic accident 3 Yes Placebo
52 F 14 A Th 4 Traffic accident 21 No No
27 M 13 A Th 5 Work accident 11 No No
42 M 22 A Th 1 Traffic accident 2.4 Yes GH
Table 2 Statistical similarity of placebo and GH-treated groups.
Placebo GH P-Value
Sex (M/F) 5M 1F 7M 1
Age (year) 35.8 (±13.4) 37.0 (±10.7) 1
BMI (kg/m2) 25.5 (±3.0) 26.6 (±3.8) 0.71
Abd perimeter (cm) 101.8 (±5.8) 105.5(±11.2) 0.76
Time from injury (months) 19.6 (±5.0) 16.9 (±9.0) 0.82
IGF1 (ng/mL) 218 ± 56.5 189.1 ± 53.5 0.34
Peak GH (ng/mL) 5.3 (±2.4) 1.8 (±2.0)* 0.034
Cortisol (µg/dL) 10.6 (±3.7) 11.7 (±3.3) 0.79
TSH (µIU/mL) 1.7 (±0.4) 2.2 (±1.1) 0.34
Values expressed as mean ± s.d.
*P < 0.05.
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for 12 patients who completed the study (7 GH and 5 
placebo) (Fig. 1).
7/12 showed a peak GH <3 ng/mL indicating severe 
deficiency. Individual clinical data are shown on Table 1.
Except for sex (12 male, 1 female), both groups 
were statistically similar according to time from injury, 
19.6 months (±5.0) vs 16.9 months (±9.0); age, 35.8 (±13.4) 
vs 37.0 (±10.7); BMI, 25.5 (±3.0) kg/m2 vs 26.6 (±3.8) kg/m2; 
waist circumference, 101.8 (±5.8) cm vs 105.5 (±11.2) cm or 
baseline IGF1 levels, 218 ± 56.5 ng/mL vs 189.1 ± 53.5 ng/mL, 
respectively in the placebo and the GH-treated groups 
(Table  2). These results are in accordance with the 
published SCI Spanish population characteristics (24, 25).
No biochemical differences were observed comparing 
lipid profile or glucose levels. Only peak GH was lower in 
the GH-treated group: 1.8 (±2.0) ng/mL vs 5.3 (±2.4) ng/mL 
in the placebo group (Mann–Whitney U; P = 0.0348), even 
after multiple adjustment, suggesting a higher degree 
of GH deficiency in the GH-treated group. All patients 
showed normal cortisol and TSH values.
Empty sella was observed in one patient, at 
baseline MRI.
Changes in the SCI assessment
We did not observe any change in motor or sensory AIS 
scale between groups (Mann–Whitney test, P > 0.05).
When analyzing SCIM-III results, no differences were 
observed between treatment groups at any visit (Mann–
Whitney test, P > 0.05). However, in the GH group, the 
change at T6 was statistically significant compared to 
baseline (Wilcoxon sign-rank test, P = 0.031).
There were not significant changes in modified 
Ashworth scale (spasticity), neither in doses of anti-
spastic treatment throughout the study and no significant 
GH-related adverse events (carpal tunnel syndrome, 
headache, maleolar edema) were described.
MEPs and SEPs
MEPs in all recorded muscles and SEPs were absent 
bilaterally at baseline in all patients and remained absent 
at 6 months of treatment in both group.
Changes in EPT and EPPT over time
The intra-individual analysis of EPT (Friedman test) 
improved during GH treatment and the differences 
reached significant level at the 5th level below the lesion, 
bilaterally, within the first 6 months of GH treatment with 
respect to baseline condition (P = 0.04). Here, the electric 
intensity (mA) needed to induce electric perception on 
the patient was significantly smaller at T6 compared with 
baseline intensity. At T6 within the placebo group, EPT 
did not show significant improvement at any level of SCI 
(P > 0.05; Fig. 2).
EPT was statistically different comparing GH 
compared to placebo group (mixed linear model analysis), 
P = 0.023 for left side at T6, and P = 0.031 for right side at 
T6 (Table 3).
Changes in EPPT were not significant at any level 
of SCI within any treatment group (P > 0.05 for each 
comparison with respect to baseline in GH and placebo 
group; Fig. 3), neither between groups.
Figure 2
Electric perception threshold (EPT) diagram. 
Intra-individual assessment. X: electric amperage 
(mA) needed for inducing sensorial perception.  
Y: mean values drawn at +5, +2 and +1 levels 
above, at level (0), and at −1, −2 and −5 levels 
below the neurological level of injury. Mean 
values are presented for baseline and 1, 3 and 
6 months after initiation of treatment. P ≤ 0.05, 
according to Wilcoxon t test.
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IGF1 values (ng/mL) were higher at 1st, 291.5 (±106.9) 
vs 200.6 (±55.9); 3rd, 296.4 (±128.4) vs 206.0 (±46.9) and 
6th months, 265.0 (±90.4) vs 207.6 (±36.5), comparing 
GH-treated group to placebo, but these differences were 
not statistically significant. No correlation between 
changes in IGF1 values (final vs baseline, and 1st/3rd 
month vs baseline) and clinical changes was found.
Discussion
Although assessed in a small number of patients, our study 
shows that long-term GH suboptimal secretion seems to 
be quite frequent (13/19) following traumatic complete 
SCI and that GH replacement therapy improves quality of 
life and, strikingly, sensory deficit below SCI.
Insulin tolerance test (ITT) should have been the gold 
standard method to assess GH deficiency, but glucagon test 
(GHRH+Arg being not available in Spain) was considered 
the safer diagnostic tool by our Ethics Committee due to 
the seizures’ risk by inducing hypoglycemia with ITT in 
patients with a very compromised mobility.
Although 13/19 patients had a peak <10 ng/mL after 
glucagon test, suggesting a suboptimal pituitary GH 
secretion, only 7/12 patients had a peak GH <3 ng/mL, 
accepted cut-off value for the diagnostic of severe GH 
deficiency (16). Recent data suggest an even lower cut-
off point for GH in overweight/obese people (a frequent 
condition in SCI population) (25) using glucagon test 
(17). Only 3/12 patients of our cohort showed that 
degree of severity (peak GH <1 ng/mL). Any other 
pituitary deficiencies (including diabetes insipidus) 
were not detected in our cohort at baseline, suggesting 
that the somatotroph axis is the most sensible one 
following trauma injuries. This has already been reported 
in GH-associated TBI. However, our prevalence seems 
higher than published TBI cohorts using similar methods 
(25% of patients remaining GH-deficient after 1 year) (3).
It is difficult to understand how dorsal spinal damage 
may influence pituitary secretion much more than direct 
cranial traumatism. We may wonder they have received a 
simultaneous brain impact, and this may partially affect 
their GH secretion capacity.
However in our cohort, TBI was an exclusion criteria, 
low Glasgow score was not reported in any of the reviewed 
clinical histories at onset and all initial cranial MRI were 
described as normal. Some of the screened patients had 
SCI from fire shot, falling from horse or bicycle without 
any direct brain trauma (Table  1). Therefore our study 
supports the idea that there should be another connection 
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To our knowledge there is no evidence in humans or 
animals of spinal neurological pathways acting through 
hypothalamic areas involved in the control of GH axis. 
We may wonder that lower back injuries induce a ‘hinge’ 
effect in the spine, which is finally driven to the pituitary 
stalk as a possible mechanic etiology. However, no 
anatomic changes were seen in the pituitary MRI, except 
for 1 empty sella.
This is the first pilot study done in vivo with complete 
SCI and concomitant low GH secretion levels.
It is important to highlight that our aim was to 
replace these patients in a physiologic manner, up and 
down-titrating the dosage according to IGF1 levels, rather 
than treating any spine lesion with GH, without knowing 
their pituitary status. We deeply think that this approach 
is particularly important in terms of safety and to avoid 
any expectations that could lead to un-labeled use.
Our aim was to assess the patients in the worst 
possible clinical situation, which is a complete AIS-A 
injury (motor and sensory failure) and lasting for at least 
12 months (no spontaneous recovery of either motor or 
sensorial are supposed to happen after this time point). 
This approach and the limitation of our study only to 
thoracic lesions have certainly reduced the number 
of potential participants in the trial, but strengthen 
our results.
As expected in large time-lapse injuries, physical 
therapy in chronic patients did not improve functional 
parameters (SCIM-III) in the placebo group, enhancing 
the need of much more precocious rehabilitation (26). 
However at 6-month evaluation, GH-treated group 
showed a better SCIM score than baseline, suggesting a 
direct effect of GH in functional recovery and quality of 
life. We can hypothesize it to be a neurological effect or 
rather a GH-driven muscular activity changes (27). In 
our study, no changes in spasticity (Ashworth test) or 
dosage of anti-spastic medication were observed and we 
did neither observe any change in upper or lower limbs 
diameter, to hypothesize direct muscular effect of GH.
Although no significant changes were seen with 
light touch sensorial physical examination (AIS scale 
examination), rejecting therefore any idea of immediate 
clinical recovery, those patients with GH treatment 
showed significant improvement in sensory perception 
at 5th level of injury in both sides following 6 months 
of treatment, when using a highly sensible quantitative 
sensory testing (Figs 2 and 3).
It is unclear how GH (together with intense physical 
therapy) may induce a partial, subclinical, sensory 
recovery of the nerve. It has been pointed out that 
intense exercise promotes activity-induced neuronal 
plasticity (28, 29), but GH could play a key role in 
enhancing this plasticity since the placebo group (which 
also received physical therapy sessions) did not showed 
any electric change in any visit. We can speculate on 
the direct central nervous system effect of GH-, IGF1- or 
GH-related peptides, such as ghrelin since receptors for 
these hormones have been found in all neural cell types. 
GH effect on proliferation, differentiation, migration and 
survival of astrocytes, oligodendrocytes and neural stem 
cells have already been proven in spine injury animal 
models (8, 9, 10, 12). A GH-mediated neuronal anti-
apoptotic effect (via Akt signaling pathway) has been 
proved in vitro both in animal and humans cells (13). We 
can also hypothesize that this neurological protective 
effect of GH could also be driven through vascular 
Figure 3
Electric pain perception threshold (EPPT) diagram. 
Intra-individual assessment. X: electric amperage 
(mA) needed for inducing pain. Y: mean values 
drawn at +5, +2 and +1 levels above, at level (0), 
and at −1, −2 and −5 levels below the 
neurological level of injury. Mean values are 
presented for baseline and 1, 3 and 6 months 
after the initiation of treatment.
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pathways since IGF1 is known to modify endothelial 
function (30).
Although it is accepted that a chronic lesion starts at 
1 year after the injury, spontaneous functional recovery 
occurs in number of incomplete SCI patients as well as in 
animal models, with time courses ranging from months 
to years (31).
This is only a pilot study, done with a small number 
of patients. Before claiming benefits with impact on daily 
life, larger and complementary studies (higher dosage 
regime, longer time after injury, efficacy assessment in 
acute or incomplete (AIS-B, C or D) spine injuries) should 
be done. Despite some hypothesis based on transitional 
models, we still do not clearly understand by which 
physiological mechanism GH replacement combined to 
physical therapy might be beneficial in SCI.
Declaration of interest
The authors declare that there is no conflict of interest that could be 
perceived as prejudicing the impartiality of the research reported.
Funding
This research was partially financed as an external sponsored study, with a 
grant by Ipsen Pharma S.A. Recombinant GH and placebo were provided 
by Ipsen Pharma S.A.
References
 1 Pellecchia MT, Pivonello R, Monsurrò MR, Trojsi F, Longo K, 
Piccirillo G, Pivonello C, Rocco M, Di Somma C, Colao A, et al. 
The GH-IGF system in amyotrophic lateral sclerosis: correlations 
between pituitary GH secretion capacity, insulin-like growth factors 
and clinical features. European Journal of Neurology 2010 17 666–671. 
(https://doi.org/10.1111/j.1468-1331.2009.02896.x)
 2 Poljakovic Z, Zurak N, Brinar V, Korsic M, Basic S & Hajnsek S. 
Growth hormone and insulin growth factor-I levels in plasma 
and cerebrospinal fluid of patients with multiple sclerosis. Clinical 
Neurology and Neurosurgery 2006 108 255–258. (https://doi.
org/10.1016/j.clineuro.2005.11.014)
 3 Schneider HJ, Kreitschmann-Andermahr I, Ghigo E, Stalla GK & 
Agha A. Hypothalamopituitary dysfunction following traumatic 
brain injury and aneurysmal subarachnoid hemorrhage: a systematic 
review. JAMA 2007 298 1429–1438. (https://doi.org/10.1001/
jama.298.12.1429)
 4 Bauman WA, Zhang RL & Spungen AM. Provocative stimulation of 
growth hormone: a monozygotic twin study discordant for spinal 
cord injury. Journal of Spinal Cord Medicine 2007 30 467–472. (https://
doi.org/10.1080/10790268.2007.11754579)
 5 Shetty KR, Sutton CH, Mattson DE & Rudman D. 
Hyposomatomedinemia in quadriplegic men. American Journal of 
Medicine 1993 305 95–100. (https://doi.org/10.1097/00000441-
199302000-00006)
 6 Sebastià-Alcácer V, Alcanyis-Alberola M, Giner-Pascual M & 
Gomez-Pajares F. Are the characteristics of the patient with a spinal 
cord injury changing? Spinal Cord 2014 52 29–33. (https://doi.
org/10.1038/sc.2013.128)
 7 Devesa J, Reimunde P, Devesa A, Souto S, Lopez-Amado M, Devesa P 
& Arce V. Recovery from neurological sequelae secondary to 
oncological brain surgery in an adult growth hormone deficient 
patient after Growth Hormone treatment. Journal of Rehabilitation 
Medicine 2009 41 775–777. (https://doi.org/10.2340/16501977-
0416)
 8 Winkler T, Sharma HS, Stålberg E, Badgaiyan RD, Westman J & 
Nyberg F. Growth hormone attenuates alterations in spinal cord 
evoked potentials and cell injury following trauma to the rat spinal 
cord. An experimental study using topical application of rat growth 
hormone. Amino Acids 2000 19 363–371. (https://doi.org/10.1007/
s007260070067)
 9 Muresanu DF, Sharma A, Lafuente JV, Patnaik R, Tian ZR, Nyberg F 
& Sharma HS. Nanowired delivery of Growth Hormone attenuates 
pathophysiology of spinal cord injury and enhances insulin-like 
growth Factor-1 concentration in the plasma and the spinal cord. 
Molecular Neurobiology 2015 52 837–845. (https://doi.org/10.1007/
s12035-015-9298-8)
 10 Fields DP, Miranpuri SS, Miranpuri GS & Resnick DK. The 
multifunctional and multi-system influence of ghrelin in the 
treatment of diabetic and spinal cord injury induced Neuropathy. 
Annals of Neurosciences 2011 18 118–122. (https://doi.org/10.5214/
ans.0972.7531.1118309)
 11 Cuatrecasas G, Alegre C, Fernandez-Solà J, Gonzalez MJ, Garcia-
Fructuoso F, Poca-Dias V, Nadal A, Cuatrecasas G, Navarro F, Mera A, 
et al. Growth hormone treatment for sustained pain reduction and 
improvement in quality of life in severe fibromyalgia. Pain 2012 153 
1382–1389. (https://doi.org/10.1016/j.pain.2012.02.012)
 12 Aberg ND, Johansson I, Aberg MA, Lind J, Johansson UE, Cooper-
Kuhn CM, Kuhn HG & Isgaard J. Peripheral administration of GH 
induces cell proliferation in the brain of adult hypophysectomized 
rats. Journal of Endocrinology 2009 201 141–150. (https://doi.
org/10.1677/JOE-08-0495)
 13 Baudet ML, Rattray D, Martin BT & Harvey S. Growth hormone 
promotes axon growth in the developing nervous system. Endocrinology 
2009 150 2758–2766. (https://doi.org/10.1210/en.2008-1242)
 14 Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, 
Devereaux PJ, Elbourne D, Egger M, Altman DG & CONSORT. 
CONSORT 2010 explanation and elaboration: updated guidelines 
for reporting parallel group randomised trials. International 
Journal of Surgery 2012 10 28–55. (https://doi.org/10.1016/j.
ijsu.2011.10.001)
 15 Kirshblum SC, Burns SP, Biering-Sorensen F, Donovan W, Graves DE, 
Jha A, Johansen M, Jones L, Krassioukov A, Mulcahey MJ, et al. 
American Spinal Injury Association (ASIA) impairment scale (AIS). 
International standards for neurological classification of spinal 
cord injury (revised 2011). Journal of Spinal Cord Medicine 2011 34 
535–546. (https://doi.org/10.1179/204577211X13207446293695)
 16 Conceiçao FL, Da Costa e Silva A, Leal Costa AJ & Vaisman M. 
Glucagon stimulation test for the diagnosis of GH deficiency in 
adults. Journal of Endocrinological Investigation 2003 26 1065–1070. 
(https://doi.org/10.1007/BF03345251)
 17 Hamrahian AH, Yuen KC, Gordon MB, Pulaski-Liebert KJ, Bena J 
& Biller BM. Revised GH and cortisol cut-points for the glucagon 
stimulation test in the evaluation of GH and hypothalamic-pituitary-
adrenal axes in adults: results from a prospective randomized 
multicenter study. Pituitary 2016 19 332–341. (https://doi.
org/10.1007/s11102-016-0712-7)
 18 Kretzer RM. A clinical perspective and definition of spinal cord 
injury. Spine 2016 41 (Supplement 7) S27. (https://doi.org/10.1097/
BRS.0000000000001432)
 19 Aguilar-Rodríguez M, Peña-Pachés L, Grao-Castellote C, Torralba-
Collados F, Hervás-Marín D & Giner-Pascual M. Adaptation and 
validation of the Spanish self-report version of the Spinal Cord 
Independence Measure (SCIM III). Spinal Cord 2015 53 451–454. 
(https://doi.org/10.1038/sc.2014.225)
This work is licensed under a Creative Commons 
Attribution-NonCommercial 4.0 International 
License.
https://doi.org/10.1530/EC-18-0296
https://ec.bioscientifica.com © 2018 The authors
Published by Bioscientifica Ltd
G Cuatrecasas et al. GH treatment in spinal cord 
injuries
10397:10
 20 Ansari NN, Naghdi S, Arab TK & Jalaie S. The interrater and intrarater 
reliability of the modified Ashworth Scale in the assessment of 
muscle spasticity: limb and muscle group effect. NeuroRehabilitation 
2008 23 231–237.
 21 Van Hedel HJ, Kumru H, Röhrich F, Galen S & EM-SCI Study group. 
Changes in electrical perception threshold within the first 6 months 
after traumatic spinal cord injury: a multicenter responsiveness 
study. Neurorehabilitation and Neural Repair 2012 26 497–506. 
(https://doi.org/10.1177/1545968311423669)
 22 Rousson V, Gasser T & Seifert B. Assessing intrarater, interrater 
and test-retest reliability of continuous measurements. Statistics in 
Medicine 2002 21 3431–3446. (https://doi.org/10.1002/sim.1253)
 23 Husted JA, Cook RJ, Farewell VT & Gladman DD. Methods for 
assessing responsiveness: a critical review and recommendations. 
Journal of Clinical Epidemiology 2000 53 459–468.
 24 Mazaira J, Labanda F, Romero J, Garcia ME, Gambarruta C, Sanchez A, 
Alcaraz MA, Arroyo O, Esclarin A, Arzoz T, et al. Epidemiología de la 
lesión medular y otros aspectos. Rehabilitación 1998 32 365–372.
 25 Bauman WA & Spungen AM. Disorders of carbohydrate and lipid 
metabolism in veterans with paraplegia or quadriplegia: a model 
of premature aging. Metabolism: Clinical and Experimental 1994 43 
749–756. (https://doi.org/10.1016/0026-0495(94)90126-0)
 26 Norrie BA, Nevett-Duchcherer JM & Gorassini MA. Reduced 
functional recovery by delaying motor training after spinal cord 
injury. Journal of Neurophysiology 2005 94 255–264. (https://doi.
org/10.1152/jn.00970.2004)
 27 Chikani V & Ho KK. Action of GH on skeletal muscle function: 
molecular and metabolic mechanisms. Journal of Molecular 
Endocrinology 2013 52 R107–R123. (https://doi.org/10.1530/ 
JME-13-0208)
 28 -Lynskey JV, Belanger A & Jung R. Activity-dependent plasticity in 
spinal cord injury. Journal of Rehabilitation Research and Development 
2008 45 229–240. (https://doi.org/10.1682/JRRD.2007.03.0047)
 29 Dunlop SA. Activity-dependent plasticity: implications for recovery 
after spinal cord injury. Trends in Neurosciences 2008 31 410–418. 
(https://doi.org/10.1016/j.tins.2008.05.004)
 30 Cittadini A, Monti MG, Castiello MC, D'Arco E, Galasso G, 
Sorriento D, Saldamarco L, De Paulis A, Napoli R, Iaccarino G, et al. 
Insulin-like growth factor-1 protects from vascular stenosis and 
accelerates re-endothelialization in a rat model of carotid artery 
injury. Journal of Thrombosis and Haemostasis 2009 7 1920–1928. 
(https://doi.org/10.1111/j.1538-7836.2009.03607.x)
 31 Hilton BJ, Anenberg E, Harrison TC, Boyd JD, Murphy TH & 
Tetzlaff W. Re-establishment of cortical motor output maps and 
spontaneous functional recovery via spared dorsolaterally projecting 
corticospinal neurons after dorsal column spinal cord injury in 
adult mice. Journal of Neuroscience 2016 36 4080–4092. (https://doi.
org/10.1523/JNEUROSCI.3386-15.2016)
Received in final form 27 July 2018
Accepted 13 August 2018
This work is licensed under a Creative Commons 
Attribution-NonCommercial 4.0 International 
License.
https://doi.org/10.1530/EC-18-0296
https://ec.bioscientifica.com © 2018 The authors
Published by Bioscientifica Ltd
